Press Releases

BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

By Lauren Vagnone | November 5, 2018

BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

Acquisition increases BioIVT’s supply of leukopaks, plasma, and sera, and enhances its ability to support the in vitro diagnostic market.

Read more

BioIVT Appoints Alan Findlater as Chief Commercial Officer

By Lauren Vagnone | October 25, 2018

BioIVT Appoints Alan Findlater as Chief Commercial Officer

BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services.

Read more

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

By Lauren Vagnone | October 16, 2018

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

QMS, Master Control will help to ensure consistent document tracking and training across all BioIVT sites and support the company’s rapid growth

Read more

BioIVT Acquires UK-based Clinical Trials Laboratory Services

By Lauren Vagnone | October 8, 2018

Acquiring this donor center and laboratory will enable BioIVT to ship high-quality blood products and blood-derived immune cells efficiently to researchers throughout Europe

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also has full-service cell processing capabilities on site.

Read more

BioIVT to Host the 2018 HEPATOPAC® User Group Meeting in Boston

By Lauren Vagnone | September 25, 2018

HEPATOPAC bioengineered micro-liver platforms are widely used for drug efficacy and safety research.

BioIVT, a leading provider of research models and services for drug development, today announced that it will be hosting the 2018 HEPATOPAC User Group Meeting (UGM) from 8:30 a.m. to 4:30 p.m. ET on Oct. 18 in Boston, MA.

Read more

BioIVT Publishes New Research On the Mechanisms Underlying the C-DILI Assay

By Lauren Vagnone | September 10, 2018

The C-DILI™ Assay is a highly effective tool for assessing cholestatic hepatotoxicity risk of promising new drug candidates.

BioIVT, a leading provider of research models and services for drug development, today announced its research into the mechanisms involved in cholestatic drug-induced liver injury (DILI) has been published in Applied In Vitro Toxicology.

Read more

BioIVT Launches Dissociated Tumor Cell (DTC) Product Line to Advance Oncology Research

By Lauren Vagnone | September 6, 2018

DTCs are primary cancer cells that are prepared with minimal manipulation and closely mimic tumor behavior.

BioIVT, a leading provider of research models and services for drug development, today announced the addition of a dissociated tumor cell (DTC) product line to its immunology portfolio.

Read more

BioIVT Webinar Will Discuss How to Optimize Microbiome Research

By Lauren Vagnone | July 19, 2018

Sample collection and processing techniques play a crucial role in ensuring that research results represent the complete microbiome.

BioIVT, a leading provider of research models and services for drug development, today announced that it is hosting a webinar entitled “The Microbiome: Understanding Why Collection and Processing Matters” at 11 a.m. ET on July 25.

Read more

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

By Lauren Vagnone | July 9, 2018

Acquisition strengthens BioIVT’s transporter sciences capabilities and enables it to partner with customers on new drug applications and mechanistic studies related to transporters.

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.

Read more

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

By Lauren Vagnone | June 28, 2018

Research using BioIVT’s TRANSPORTER CERTIFIED™ hepatocytes in sandwich culture and HEPATOPAC® technology in vitro liver models will be presented.

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.

Read more